Company / Current Liabilities
Rein Therapeutics, Inc. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$6.2M
FY2025
5-year range
$3.4M / $6.2M
FY2021-FY2025
Trend
+7.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has increased for 3 consecutive years, from $3M in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +9.3%.
Increased from $4M to $6M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +22.2%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Rein Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2025, current liabilities increased 7.5% year-over-year.
- Lowest current liabilities in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2M | +7.5% |
| FY2024 | $5.7M | +31.1% |
| FY2023 | $4.4M | +29.6% |
| FY2022 | $3.4M | -24.9% |
| FY2021 | $4.5M | +13.8% |
| FY2020 | $4.0M | -32.2% |
| FY2019 | $5.8M | +8.7% |
| FY2018 | $5.4M | +9.8% |
| FY2017 | $4.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026